SEPN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

4 Analyst Rating

Wall Street analysts forecast SEPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEPN is 27.67 USD with a low forecast of 25.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

27.67

High

30.00

Current: 0.000

Low

25.00

Averages

27.67

High

30.00

JonesResearch

NULL -> Buy

initiated

$43

2025-12-23

Reason

JonesResearch

Price Target

$43

2025-12-23

initiated

NULL -> Buy

Reason

JonesResearch initiated coverage of Septerna with a Buy rating and $43 price target. Septerna is a clinical stage biotech focused on identifying novel ways to target G protein-coupled receptors with small molecules, the analyst tells investors in a research note. The firm says the company's lead endocrine program is SEP-479 for hypoparathyroidism with a Phase 1 initiating in the first half of 2026. Jones forecasts $2.5B in unadjusted U.S. peak sales in 2035.

Truist

initiated

$34

2025-12-15

Reason

Truist

Price Target

$34

2025-12-15

initiated

Reason

Truist initiated coverage of Septerna with a Buy rating and $34 price target. The firm says the company's SEP-631 is in Phase 1 for chronic spontaneous urticaria and presents novel oral option for a multi-billion market opportunity. The firm views the data in the first half of 2026 as a key catalyst for the shares.

JPMorgan

NULL -> Overweight

upgrade

$28 -> $34

2025-11-18

Reason

JPMorgan

Price Target

$28 -> $34

2025-11-18

upgrade

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Septerna to $34 from $28 and keeps an Overweight rating on the shares following a transfer of coverage. The firm remains "optimistic" about the stock's potential upside as the company's Native Complex Platform platform is validated.

Wells Fargo

Derek Archila

Equal Weight -> Overweight

upgrade

$18 -> $28

2025-11-14

Reason

Wells Fargo

Derek Archila

Price Target

$18 -> $28

2025-11-14

upgrade

Equal Weight -> Overweight

Reason

Wells Fargo analyst Derek Archila upgraded Septerna to Overweight from Equal Weight with a price target of $28, up from $18.

Wells Fargo

Equal Weight -> Overweight

upgrade

$18 -> $28

2025-11-14

Reason

Wells Fargo

Price Target

$18 -> $28

2025-11-14

upgrade

Equal Weight -> Overweight

Reason

Wells Fargo upgraded Septerna to Overweight from Equal Weight with a price target of $28, up from $18, after hosting investor meetings with management. The firm "gained confidence" on SEP-479's safety profile and its "differentiation" relative to Septerna's prior program. Wells sees SEP-479's advancement into Phase 1 and SEP-631's Phase 1 update in the first half of 2026 as key catalysts for the stock.

H.C. Wainwright

Buy

maintain

$26 -> $30

2025-11-11

Reason

H.C. Wainwright

Price Target

$26 -> $30

2025-11-11

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Septerna to $30 from $26 and keeps a Buy rating on the shares. The firm says the SEP-631 clinical data release is on track for a first half of 2026 readout.

Valuation Metrics

The current forward P/E ratio for Septerna Inc (SEPN.O) is -100.58, compared to its 5-year average forward P/E of -22.69. For a more detailed relative valuation and DCF analysis to assess Septerna Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-22.69

Current PE

-100.58

Overvalued PE

10.05

Undervalued PE

-55.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.28

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.25

Undervalued EV/EBITDA

-4.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

137.01

Current PS

14.99

Overvalued PS

436.97

Undervalued PS

-162.94

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SEPN News & Events

Events Timeline

No data

News

8.5

01-09renaissancecapital

Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly

5.0

01-08Globenewswire

Septerna Appoints Mark A. Wilson as Chief Legal Officer to Enhance Governance

6.0

2025-12-23Benzinga

Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street

People Also Watch

Frequently Asked Questions

What is Septerna Inc (SEPN) stock price today?

The current price of SEPN is 25.3 USD — it has decreased -1.71 % in the last trading day.

What is Septerna Inc (SEPN)'s business?

Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

What is the price predicton of SEPN Stock?

What is Septerna Inc (SEPN)'s revenue for the last quarter?

Septerna Inc revenue for the last quarter amounts to 21.50M USD, increased 12113.07 % YoY.

What is Septerna Inc (SEPN)'s earnings per share (EPS) for the last quarter?

Septerna Inc. EPS for the last quarter amounts to 0.18 USD, decreased -102.14 % YoY.

What changes have occurred in the market's expectations for Septerna Inc (SEPN)'s fundamentals?

The market is revising Downward the revenue expectations for Septerna, Inc. (SEPN) for FY2025, with the revenue forecasts being adjusted by -54.64% over the past three months. During the same period, the stock price has changed by 9.33%.

How many employees does Septerna Inc (SEPN). have?

Septerna Inc (SEPN) has 75 emplpoyees as of January 10 2026.

What is Septerna Inc (SEPN) market cap?

Today SEPN has the market capitalization of 1.13B USD.